Measurable Residual Disease (MRD)
3 clinical trials · Condition
◉ Watch Measurable Residual Disease (MRD)
| Record | Firm | Date |
|---|---|---|
| Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (NCT04827745) | University of Maryland, Baltimore | 2021-06-11 |
Track Measurable Residual Disease (MRD) automatically
Every clearance here is in the API, with alerts when new ones post.